BioAdvance is an evergreen fund established to address the shortage of seed and pre-seed capital for companies developing new technologies to improve human health.

BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its $20 million Greenhouse Fund. We invest in therapeutics, devices, diagnostics and platform technologies focused on human health.

Since its first investments in 2003, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date we have committed $19.9 million to 29 seed-stage companies and 19 pre-seed investments. Our portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance investments have enabled its portfolio companies to leverage more than $1.4 billion in subsequent capital into the region (from private equity, grants, collaborations and M&A activity).